BVS logo

BVS
Bioventus Inc - Ordinary Shares - Class A

446
Mkt Cap
$913.87M
Volume
1.52M
52W High
$11.25
52W Low
$5.81
PE Ratio
23.03
BVS Fundamentals
Price
$9.50
Prev Close
$10.94
Open
$10.82
50D MA
$9.70
Beta
1.15
Avg. Volume
440,950.31
EPS (Annual)
$0.3299
P/B
3.40
Rev/Employee
$610,846.24
$817.18
Loading...
Loading...
News
all
press releases
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
News Placeholder
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?
The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
News Placeholder
Bioventus (NASDAQ:BVS) Reaches New 1-Year High on Better-Than-Expected Earnings
Bioventus (NASDAQ:BVS) Sets New 12-Month High on Earnings Beat...
News Placeholder
Bioventus Q1 Earnings Call Highlights
Bioventus (NASDAQ:BVS) reported first-quarter 2026 results that management said put the company "off to a strong start" as it increased investment in several growth drivers while still expanding profitability and cash generation. On the call, the company also raised guidance for adjusted earnings pe...
News Placeholder
Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates
Bioventus (BVS) delivered earnings and revenue surprises of +76.47% and +2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Bioventus (NASDAQ:BVS) Updates FY 2026 Earnings Guidance
Bioventus (NASDAQ:BVS) updated its FY 2026 earnings guidance. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus estimate of 0.750. The company also issued...
News Placeholder
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
News Placeholder
Bioventus Inc. (NASDAQ:BVS) Given Average Rating of "Buy" by Brokerages
Shares of Bioventus Inc. (NASDAQ:BVS - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are currently covering the firm, Marketbeat reports. One equities...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available